Short answer
Johnson & Johnson (JNJ) filed its Q3 2026 10-Q quarterly report on Oct 21, 2026 for the quarter ended Sep 27, 2026. Quarterly revenue was $25.4B (up 5.9% year over year) with net income of $210M.
Q3 2026 key financials · XBRL
- Revenue
- $25.4B
- +5.9% YoY · +0.4% QoQ
- Net income
- $210M
- −95.9% YoY · −96.2% QoQ
- Gross margin
- 68.1%
- EPS (diluted)
- $0.08
- −96.2% YoY · −96.5% QoQ
Source: XBRL data from the Johnson & Johnson (JNJ) Q3 2026 10-Q on SEC EDGAR. USD.
Johnson & Johnson Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Emerging risks: pricing pressure, patent expirations, litigation, tariffs, supply-chain disruptions
- Planned Orthopaedics separation: timing, execution, and anticipated benefits remain uncertain
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Johnson & Johnson quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.